A novel trypsin Kazal-type inhibitor from Aedes aegypti with thrombin coagulant inhibitory activity
Biochemistry paper published in Biochimie (2010)
Abstract
Kazal-type inhibitors play several important roles in invertebrates, such as anticoagulant, vasodilator and antimicrobial activities. Putative Kazal-type inhibitors were described in several insect transcriptomes. In this paper we characterized for the first time a Kazal unique domain trypsin inhibitor from the Aedes aegypti mosquito. Previously, analyses of sialotranscriptome of A. aegypti showed the potential presence of a Kazal-type serine protease inhibitor, in female salivary glands, carcass and also in whole male, which we named AaTI (A. aegypti trypsin inhibitor). AaTI sequence showed amino acid sequence similarity with insect thrombin inhibitors, serine protease inhibitor from Litopenaeus vannamei hemocytes and tryptase inhibitor from leech Hirudo medicinalis (LDTI). In this work we expressed, purified and characterized the recombinant AaTI (rAaTI). Molecular weight of purified rAaTI was 7 kDa rAaTI presented dissociation constant (K(i)) of 0.15 and 3.8 nM toward trypsin and plasmin, respectively, and it weakly inhibited thrombin amidolytic activity. The rAaTI was also able to prolong prothrombin time, activated partial thromboplastin time and thrombin time. AaTI transcription was confirmed in A. aegypti female salivary gland and gut 3 h and 24 h after blood feeding, suggesting that this molecule can act as anticoagulant during the feeding and digestive processes. Its transcription in larvae and pupae suggested that AaTI may also play other functions during the mosquito's development.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Kazal-type inhibitor AaTI from Aedes aegypti sialotranscriptome shows sequence similarity to leech Hirudo medicinalis tryptase inhibitor LDTI — supports the conservation of hematophagy-associated anti-coagulation proteins across phyla.
Por qué esto importa para la hirudoterapia
Este estudio caracterizó AaTI, un nuevo inhibidor de tripsina de tipo Kazal del mosquito Aedes aegypti, que mostró similitud en la secuencia de aminoácidos con inhibidores de trombina de insectos y con el inhibidor de triptasa LDTI de la sanguijuela Hirudo medicinalis. La AaTI recombinante (7 kDa) inhibió la tripsina (Ki 0,15 nM) y la plasmina (Ki 3,8 nM), inhibió débilmente la actividad amidolítica de la trombina y prolongó el tiempo de protrombina, el tiempo de tromboplastina parcial activada y el tiempo de trombina. La relevancia con el ámbito de ASH es indirecta: el estudio identifica una clase estructural y funcional de inhibidores de serina proteasas (tipo Kazal) que incluye moléculas derivadas de sanguijuelas como LDTI, lo que sugiere estrategias moleculares compartidas entre invertebrados hematófagos para facilitar la alimentación sanguínea mediante anticoagulación. Advertencia: este estudio se refiere a una proteína de mosquito, no a sanguijuelas ni a sustancias derivadas de sanguijuelas; la conexión con las sanguijuelas se limita a la homología de secuencia, y no se aislaron, analizaron ni caracterizaron componentes del secreto de sanguijuela.
Citación
A novel trypsin Kazal-type inhibitor from Aedes aegypti with thrombin coagulant inhibitory activity.
Watanabe RM et al. · Biochimie, 2010
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026